The big pharma company will no longer progress emugrobart to late-stage trials in FSHD and SMA due to a lack of efficacy.
The company discontinued developing emugrobart after two studies showed the drug didn’t achieve intended outcomes.
The main beneficiary of Roche’s discontinuation of an investigational spinal muscular atrophy drug is Scholar Rock, which was ...
Chugai announces Roche to discontinue development of emugrobart in spinal muscular atrophy and FSHD: Tokyo Tuesday, March 24, 2026, 14:00 Hrs [IST] Chugai Pharmaceutical Co., Ltd.
Data presented at the 2026 Muscular Dystrophy Association meeting could have readthroughs to companies developing therapies ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Motor function and other motor milestones were ...
At her eight-month pregnancy check-up, Lizmara Figueroa met with a new doctor. As he walked out the door, he made a parting comment. “He says, ‘Oh, just so you know, you’re a carrier for (spinal ...
The Ironman In You project aims to raise awareness on muscular dystrophy It also aims to raise money for members of the Muscular Dystrophy Association of Singapore As of June 25, this project had ...
Scotland has become the first UK nation to screen all newborn babies for spinal muscular atrophy. Here is what you need to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results